Conjugated hyperbilirubinemia in a newborn infant after maternal (transplacental) treatment with flecainide acetate for fetal tachycardia and fetal hydrops.
An infant with intrauterine supraventricular tachycardia and fetal hydrops, successfully treated with administration of flecainide acetate to the mother had conjugated hyperbilirubinemia shortly after birth. An extensive evaluation failed to disclose a known cause. We believe that in utero exposure to flecainide acetate resulted in conjugated hyperbilirubinemia in this infant.
Vanderhal
A L
AL
Division of Neonatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Cocjin
J
J
Santulli
T V
TV
Carlson
D E
DE
Rosenthal
P
P
D005260:Female; D005315:Fetal Diseases / Q000188:drug therapy*; D005424:Flecainide / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D015160:Hydrops Fetalis / Q000188:drug therapy*; D007223:Infant; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000139:chemically induced*; D008297:Male; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D013610:Tachycardia / Q000188:drug therapy*
D005424:Flecainide